Billings Clinic Dialysis, Llc is a medicare approved dialysis facility center in Billings, Montana and it has 17 dialysis stations. It is located in Yellowstone county at 2800 10th Ave N Ste D, Billings, MT, 59101. You can reach out to the office of Billings Clinic Dialysis, Llc at (406) 657-4100. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. Billings Clinic Dialysis, Llc has the following ownership type - Non-Profit. It was first certified by medicare in April, 2014. The medicare id for this facility is 272510 and it accepts patients under medicare ESRD program.
| Name | Billings Clinic Dialysis, Llc |
|---|---|
| Location | 2800 10th Ave N Ste D, Billings, Montana |
| No. of Dialysis Stations | 17 |
| Medicare ID | 272510 |
| Managed By | Dialysis Clinic, Inc. |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 2800 10th Ave N Ste D, Billings, Montana, 59101 | |
| (406) 657-4100 | |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| NPI Number | 1043634280 |
| Doing Business As | Billings Clinic Dialysis Llc |
| Address | 2800 10th Ave N Billings, Montana, 59101 |
| Phone Number | (406) 657-4100 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| NPI Number | 1306902820 |
| Organization Name | Billings Clinic Dialysis |
| Doing Business As | Billings Clinic |
| Address | 2800 10th Ave N Billings, Montana, 59101 |
| Phone Number | (406) 657-4000 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| NPI Number | 1053477547 |
| Organization Name | Absaloka Dialysis Unit |
| Doing Business As | Billings Clinic |
| Address | I 90 & 212 Crow Agency, Montana, 59022 |
| Phone Number | (406) 657-4000 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 68% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 9% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 23% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 69% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 14% |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 54% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 17% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 29% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 54% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 12% |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 74% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 26% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 59% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 12% |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| Dialysis patients with Hemoglobin data | 73 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 8 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 3 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 108 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 973 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
| Adult patients getting regular peritoneal dialysis at the center | 46 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 317 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 82 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Billings Clinic Dialysis, Llc with elevated calcium levels.
| Patients with hypercalcemia | 148 |
| Hypercalcemia patient months | 1333 |
| Patients with Serumphosphor | 169 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 19 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 27 |
| Patients with Serumphosphor greater than 7 mg/dL | 21 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 107 |
| Patient months included in arterial venous fistula and catheter summaries | 831 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 73 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 126 |
| Hospitalization Rate in facility | 125.1 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 220.2 |
| Hospitalization Rate: Lower Confidence Limit | 77.4 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Billings Clinic Dialysis, Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 15.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 23.4 |
| Readmission Rate: Lower Confidence Limit | 9.5 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Billings Clinic Dialysis, Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .28 (Better than Expected) |
| SIR: Upper Confidence Limit | .94 |
| SIR: Lower Confidence Limit | .05 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Billings Clinic Dialysis, Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 107 |
| Transfusion Rate in facility | 20.3 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 54.2 |
| Transfusion Rate: Lower Confidence Limit | 8.6 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Billings Clinic Dialysis, Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 412 |
| Mortality Rate in facility | 20.3 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 26.1 |
| Mortality Rate: Lower Confidence Limit | 15.6 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago
Billings Clinic Dialysis, Llc Location: 2800 10th Ave N Ste D, Billings, Montana, 59101 Phone: (406) 657-4100 |
News Archive
In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD.
The New York Times reports that some companies could avoid requirements in the health law by insuring their own employees - a move that might drive up costs for workers of other companies. Other outlets look at concerns that young, healthy people buying policies in new online markets could see a jump in insurance costs.
Today, the Federal Court in Australia published its judgment in the Peterson case. The Court found against MSD Australia on two claims under Australian statutory provisions. The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court's findings that were against MSD Australia and intend to appeal them.
› Verified 7 days ago